Klaria Pharma Holding AB

KLAR · Nasdaq Stockholm · Healthcare

0.59SEK −3.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: +17.3%

Performance

1 month

−6.2%

1 year

+17.3%

3 years, per year

+2.4%

5 years, per year

−38.3%

Largest fall, 3 years

−98.5%

Below the peak now

−96.3%

Volatility, 1 year

87.1%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

−5.8

Dividend yield

0.0%

Return on equity

−115.2%

Net margin

–

Market value

14 m USD

Quality, value and trend

Where Klaria Pharma Holding stands against every Nordic stock today. 100 is best.

Quality13

Profitability and a sound balance sheet over time. Better than 13% of Nordic stocks.

Value1

The price measured against earnings, assets and cash flow. Better than 1% of Nordic stocks.

Trend25

The price development over the past year. Better than 25% of Nordic stocks.

Combined1

Quality, value and trend together. Better than 1% of Nordic stocks.

About Klaria Pharma Holding

Klaria Pharma Holding AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis